The estimated Net Worth of Linda Marban is at least $1.06 Milione dollars as of 12 May 2023. Linda Marban owns over 20,749 units of Capricor Therapeutics Inc stock worth over $830,165 and over the last 10 years he sold CAPR stock worth over $0. In addition, he makes $232,909 as President, Chief Executive Officer e Director at Capricor Therapeutics Inc.
Linda has made over 5 trades of the Capricor Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 20,749 units of CAPR stock worth $28,841 on 12 May 2023.
The largest trade he's ever made was exercising 41,497 units of Capricor Therapeutics Inc stock on 27 July 2020 worth over $153,539. On average, Linda trades about 6,730 units every 188 days since 2015. As of 12 May 2023 he still owns at least 198,604 units of Capricor Therapeutics Inc stock.
You can see the complete history of Linda Marban stock trades at the bottom of the page.
Dr. Linda Marban is President, Chief Executive Officer and Director of the Company. She is Co-founder of CAPRICOR THERAPEUTICS, Dr. Marbán has been with Capricor since 2005 and became its Chief Executive Officer in 2010. She combines her background in research with her business experience to lead Capricor and create a path to commercialization for its novel stem-cell cardiac therapies. Dr. Marbán was the lead negotiator in procuring the license agreements that are the foundation of Capricor’s intellectual property portfolio. Under her direction as Chief Executive Officer, Capricor secured approximately $27.0 million in non-dilutive grants and a loan award which funds Capricor’s R&D programs and clinical trials involving its CAP-1002 product. Dr. Marbán’s deep knowledge of the cardiac space in particular allows her to provide unique direction for the company’s development and growth. From 2003 to 2009, Dr. Marbán was with Excigen, Inc., a biotechnology start-up company, where she was responsible for business development, operations, pre-clinical research, and supervising the development of gene therapy products in a joint development agreement with Genzyme Corp. While at Excigen, she also negotiated a joint development and sublicense agreement with Medtronic Corp. utilizing Excigen’s technology and supervised the building of a lab in which the work was to be performed. Dr. Marbán began her career in academic science, first at the Cleveland Clinic Foundation working on the biophysical properties of cardiac muscle. That work continued when she moved to a postdoctoral fellowship at Johns Hopkins University, or JHU. While at JHU, she advanced to the rank of Research Assistant Professor in the Department of Pediatrics, continuing her work on the mechanism of contractile dysfunction in heart failure. Her tenure at JHU ran from 2000 to 2003. Dr. Marbán earned a Ph.D. from Case Western Reserve University in cardiac physiology.
As the President, Chief Executive Officer e Director of Capricor Therapeutics Inc, the total compensation of Linda Marban at Capricor Therapeutics Inc is $232,909. There are 3 executives at Capricor Therapeutics Inc getting paid more, with Karen G. Krasney having the highest compensation of $346,750.
Linda Marban is 51, he's been the President, Chief Executive Officer e Director of Capricor Therapeutics Inc since 2014. There are 13 older and 4 younger executives at Capricor Therapeutics Inc. The oldest executive at Capricor Therapeutics Inc is Louis Grasmick, 90, who is the Independent Director.
Linda's mailing address filed with the SEC is C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO, CA, 92121.
Over the last 11 years, insiders at Capricor Therapeutics Inc have traded over $949,404,468 worth of Capricor Therapeutics Inc stock and bought 6,444,826 units worth $18,843,106 . The most active insiders traders include Sinai Medical Center Cedars, John Edward A.Edward St. Jo... e Gregory W Schafer. On average, Capricor Therapeutics Inc executives and independent directors trade stock every 58 days with the average trade being worth of $494,068. The most recent stock trade was executed by David B Musket on 7 August 2024, trading 34,000 units of CAPR stock currently worth $47,260.
capricor therapeutics, inc. (nasdaq: capr) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. capricor’s lead candidate, cap-1002, is an “off-the-shelf” cardiac cell therapy that is currently in clinical development for the treatment of duchenne muscular dystrophy (dmd). cap-1002 consists of allogeneic cardiosphere-derived cells, or cdcs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. cdcs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials. capricor has
Capricor Therapeutics Inc executives and other stock owners filed with the SEC include: